Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against chikungunya virus
Archives of Biochemistry and Biophysics · 2024-09 · 759 · 110111
DOI: 10.1016/j.abb.2024.110111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2024-09. Verfasst von Mandar Bhutkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Virology Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Uttarakhand, India. Hauptthemen laut MEDLINE: Antiviral Agents, Methyltransferases, Chikungunya virus. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Indian Institute of Technology Roorkee, Prime Minister's Office Singapore, ICMR.
Abstract (Originalsprache)
Chikungunya virus (CHIKV), transmitted by mosquitoes, poses a significant global health threat. Presently, no effective treatment options are available to reduce the disease burden. The lack of approved therapeutics against CHIKV and the complex spectrum of chronic musculoskeletal and neurological manifestations raise significant concerns, and repurposing drugs could offer swift avenues in the development of effective treatment strategies. RNA capping is a crucial step meditated by non-structural protein 1 (nsP1) in CHIKV replication. In this study, FDA-approved antivirals targeting CHIKV nsP1 methyltransferase (MTase) have been identified by structure-based virtual screening. Berbamine Hydrochloride (BH), ABT199/Venetoclax (ABT), and Ponatinib (PT) were the top-hits, which exhibited robust binding energies. Tryptophan fluorescence spectroscopy-based assay confirmed binding of BH-, ABT-, and PT to purified nsP1 with KD values ∼5.45 μM, ∼161.3 μM, and ∼3.83 μM, respectively. In a capillary electrophoresis-based assay, a decrease in CHIKV nsP1 MTase activity was observed in a dose-dependent manner. Treatment with BH, ABT, and PT lead to a dose-dependent reduction in the virus titer with IC50 1.25 μM, respectively. These results highlight the potential of repurposing drugs as rapid and effective antiviral therapeutics against CHIKV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Virology Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Uttarakhand, India.
- Molecular Virology Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Uttarakhand, India. Electronic address: shailly.tomar@bt.iitr.ac.in.
Förderung
- Indian Institute of Technology Roorkee
- Prime Minister's Office Singapore
- ICMR
- Department of Biotechnology, Ministry of Science and Technology, India
- Advanced Instrumentation Research Facility
- Indian Institute Of Petroleum, Council of Scientific and Industrial Research, India
- Institute for Bioengineering and Biosciences
- ICMR- National Institute of Virology
Zitieren
APA
Bhutkar, M., Saha, A., & Tomar, S. (2024). Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against chikungunya virus. Archives of Biochemistry and Biophysics, 759, 110111. https://doi.org/10.1016/j.abb.2024.110111
Vancouver
Bhutkar M, Saha A, Tomar S. Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against chikungunya virus. Archives of Biochemistry and Biophysics. 2024;759:110111. doi:10.1016/j.abb.2024.110111
BibTeX
@article{Bhutkar2024,
author = {Bhutkar, Mandar and Saha, Ankita and Tomar, Shailly},
title = {Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against chikungunya virus},
journal = {Archives of Biochemistry and Biophysics},
year = {2024},
volume = {759},
pages = {110111},
doi = {10.1016/j.abb.2024.110111}
}
EUVIMED